Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?

Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound grew sales 125% and 80% in Q1 2026, supporting a 56% overall sales gain, but its dividend yield is only 0.6%. Pfizer offers a much higher 6.6% yield, though it faces patent expirations, weak COVID vaccine sales, and a halted GLP-1 program; management says dividend support remains a priority despite a payout ratio above 100%. The article is a comparative stock commentary rather than new company-specific news, so the likely market impact is limited.

Analysis

The setup is less about “cheap vs expensive” and more about duration of cash flows. LLY is being priced like a multi-year secular grower with visible pricing power, while PFE is being treated like a balance-sheet-and-patent overhang story with an income backstop. That divergence creates a classic mistake investors make in healthcare: they underwrite the dividend but ignore that a >100% payout ratio can force slower buybacks, higher leverage, or a future reset if operating recovery slips.

The second-order effect is that PFE’s yield screens well for asset allocators, but that can keep a floor under the stock even as fundamentals remain mediocre. That makes this more suitable as a spread trade than a naked long: the market is already paying for the income, so upside likely requires either a credible pipeline readout or a sentiment rebound in large-cap pharma, not just “the dividend is high.” By contrast, LLY’s problem is valuation fragility, not business fragility; any disappointment in execution or competitive GLP-1 data would hit multiples faster than earnings.

The consensus is missing that the real catalyst for PFE is not the dividend itself but the next 12-18 months of pipeline de-risking and capital allocation. If management can maintain the payout while showing even one or two credible late-stage wins, the stock can rerate sharply because expectations are already compressed. If not, the yield becomes a value trap and the market will start demanding proof that cash generation can cover both R&D and distributions without financial engineering.

Key Decisions for Investors

• Go long PFE only as an income/value placeholder with a 6-12 month horizon; target 15-20% upside from multiple normalization, but size small because the dividend is financing the thesis and any cut would likely trigger a fast de-rating.
• Use a pair trade: long PFE / short LLY for investors expressing relative value between income and growth; expect lower volatility than outright long PFE, with payoff if the market over-extends LLY's multiple while PFE stabilizes on yield support.
• For tactical traders, buy PFE call spreads or a call calendar into the next pipeline event window over the next 3-9 months; risk/reward favors defined-risk upside because implied expectations are depressed, while downside is cushioned by the yield.
• Avoid initiating fresh long LLY here on valuation alone; if owning, consider trimming and rotating into higher-yield defensives, since the risk/reward is less attractive unless you have high conviction in continued GLP-1 share gains over the next 12 months.
• Watch for any signal of dividend policy stress at PFE; if payout coverage worsens, reduce exposure immediately, because the stock's main support case would be invalidated and downside could accelerate 15%+ in weeks.